The US Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne, Biocon Biologics Ltd), a biosimilar to bevacizumab (Avastin, Genentech), for intravenous use across multiple cancer ...

This approval is Biocon's seventh U.S. biosimilar, enhancing their oncology portfolio and commitment to affordable biologics. The FDA has approved Jobevne, a biosimilar to Avastin, for IV use in a ...

Leading pharmacy benefit managers are shifting away from lucrative rebates on biologic drugs and toward lower-cost biosimilar ...

Biocon Biologics has gained approval from the US Food and Drug Administration (FDA) for the intravenous use of Jobevne (bevacizumab-nwgd), a biosimilar to the reference Avastin (bevacizumab).

Celltrion Inc., a major South Korean biopharmaceutical firm, said Monday it has obtained an interchangeability approval for ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

Biocon Biologics has gained approval from the US Food and Drug Administration (FDA) for the intravenous use of Jobevne ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Biocon rose 3.10% to Rs 326.35 after the company's subsidiary Biocon Biologics signed a settlement and license agreement with Regeneron, paving the way to commercialize Yesafili, a biosimilar to EYLEA ...

In Regeneron Pharms., Inc. v. Mylan Pharms. Inc., the Federal Circuit recently held that biosimilar pharmaceutical companies that filed ...

A FDA generic drug office was eliminated — and the implications will be felt not only by drugmakers, but consumers ...